Clinical Trials Browser

Phase 2 × Active not recruiting × Breast × Clear all

NCT02398773 2026-03-18

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Phase 2 Active not recruiting

HER2/Neu Negative

NCT02482376 2026-03-17

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Phase 2 Active not recruiting

110 enrolled 18 charts

Breast Neoplasms

NCT03598257 2026-03-17

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Phase 2 Active not recruiting

Inflammatory Breast Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04001829 2026-03-13

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Phase 2 Active not recruiting

249 enrolled 14 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04293393 2026-03-12

CARABELA

Phase 2 Active not recruiting

200 enrolled 27 charts

Breast Neoplasms

NCT05865990 2026-03-12

TUXEDO-3

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms

NCT01266642 2026-03-11

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Phase 2 Active not recruiting

301 enrolled 9 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast Neoplasms

NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Phase 2 Active not recruiting

273 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT05810870 2026-03-10

SABINA

Phase 2 Active not recruiting

Breast Neoplasms

NCT06048718 2026-03-10

TUXEDO-4

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT01334021 2026-03-09

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

Phase 2 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT04829604 2026-03-09

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06604858 2026-03-09

TELESCOPE

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT03359954 2026-03-05

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Phase 2 Active not recruiting

Estrogen Receptor Positive

NCT03941730 2026-03-05

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Active not recruiting

8 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03386617 2026-03-04

AKY15-HK-301_NEPA Study

Phase 2 Active not recruiting

Breast Neoplasms

NCT06844669 2026-03-03

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Phase 2 Active not recruiting

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT04266249 2026-03-02

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT05710328 2026-03-02

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Phase 2 Active not recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT07421141 2026-02-27

Opti-HER2

Phase 2 Active not recruiting

Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Phase 2 Active not recruiting

Breast Neoplasms

NCT05721248 2026-02-20

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Phase 2 Active not recruiting

Breast Neoplasms

NCT02927912 2026-02-17

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Phase 2 Active not recruiting

Breast Neoplasms

NCT03587740 2026-02-17

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

Breast Neoplasms

NCT06068985 2026-02-12

CHERRY-PICK

Phase 2 Active not recruiting

Breast Neoplasms

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

Phase 2 Active not recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT02747004 2026-02-06

Next MONARCH 1

Phase 2 Active not recruiting

234 enrolled 20 charts

Breast Neoplasms

NCT03789110 2026-02-06

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled 15 charts

Breast Neoplasms

NCT06175390 2026-02-06

SKYLINE

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

23 enrolled 18 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03808662 2026-02-04

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT06027268 2026-02-03

ToPCourT

Phase 2 Active not recruiting

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT03624543 2026-01-30

CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT01984138 2026-01-28

REVIVE

Phase 2 Active not recruiting

Breast Neoplasms

NCT04316117 2026-01-26

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Phase 2 Active not recruiting

Breast Neoplasms

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Phase 2 Active not recruiting

71 enrolled 11 charts

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02971748 2026-01-22

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

Phase 2 Active not recruiting

36 enrolled 8 charts

Inflammatory Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Phase 2 Active not recruiting

53 enrolled 13 charts

Breast Neoplasms